Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alder Biopharmaceuticals, Inc.
Alder Biopharmaceuticals Presents Results From Phase 1 Trial of ALD518 in Advanced Cancer at American Society of Clinical Oncology Annual Meeting
June 19th, 2009
Alder Biopharmaceuticals, Inc., an emerging antibody therapeutics company, announced results from a Phase 1 clinical study of the Company’s lead monoclonal antibody therapeutic, ALD518, for treatment of advanced cancer demonstrating the drug to be safe, well-tolerated and to reduce fatigue in patients with advanced cancer. Data were presented during a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida. (ASCO Abstract No. 3025) ALD518 is a humanized anti-IL-6 antibody being developed for the treatment of cancer cachexia – unplanned weight loss, weakness, muscle atrophy -- and fatigue. The trial enrolled 9 patients...
Source: Health Business Week (2009-06-19)
|
